These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 29896291)
1. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291 [No Abstract] [Full Text] [Related]
2. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer. Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236 [TBL] [Abstract][Full Text] [Related]
3. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239 [TBL] [Abstract][Full Text] [Related]
4. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Takahashi T Lung Cancer; 2018 Jul; 121():48-53. PubMed ID: 29858026 [TBL] [Abstract][Full Text] [Related]
5. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer. Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. Otsuka K; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Yoneda H; Ogino H; Nishioka Y Thorac Cancer; 2022 Nov; 13(21):2978-2984. PubMed ID: 36106507 [TBL] [Abstract][Full Text] [Related]
7. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Izuka S; Yamashita H; Iba A; Takahashi Y; Kaneko H Rheumatology (Oxford); 2021 May; 60(5):2348-2354. PubMed ID: 33241299 [TBL] [Abstract][Full Text] [Related]
8. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. Tsutani Y; Mimura T; Kai Y; Ito M; Misumi K; Miyata Y; Okada M J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1089-1096.e1. PubMed ID: 28483268 [TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371 [TBL] [Abstract][Full Text] [Related]
10. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. Kato M; Shukuya T; Takahashi F; Mori K; Suina K; Asao T; Kanemaru R; Honma Y; Muraki K; Sugano K; Shibayama R; Koyama R; Shimada N; Takahashi K BMC Cancer; 2014 Jul; 14():508. PubMed ID: 25012241 [TBL] [Abstract][Full Text] [Related]
11. Is operation safe for lung cancer patients with interstitial lung disease on computed tomography? Tang H; Ren Y; She Y; Dai C; Wang T; Su H; Sun W; Jiang G; Chen C Ther Adv Respir Dis; 2020; 14():1753466620971137. PubMed ID: 33167797 [TBL] [Abstract][Full Text] [Related]
12. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Kakutani T; Hashimoto A; Tominaga A; Kodama K; Nogi S; Tsuno H; Ogihara H; Nunokawa T; Komiya A; Furukawa H; Tohma S; Matsui T Mod Rheumatol; 2020 May; 30(3):458-464. PubMed ID: 31116052 [No Abstract] [Full Text] [Related]
13. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy. Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339 [TBL] [Abstract][Full Text] [Related]
14. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer. Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332 [TBL] [Abstract][Full Text] [Related]
15. Effect of collagen vascular disease-associated interstitial lung disease on the outcomes of lung cancer surgery. Maeda H; Kanzaki M; Sakamoto K; Isaka T; Oyama K; Murasugi M; Onuki T Surg Today; 2017 Sep; 47(9):1072-1079. PubMed ID: 28247107 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. Koda K; Enomoto Y; Aoshima Y; Amano Y; Kato S; Hasegawa H; Matsui T; Yokomura K; Mochizuki E; Matsuura S; Koshimizu N; Morita M; Kojima S; Watanabe A; Oyama Y; Ikeda M; Kusagaya H; Uto T; Sato J; Imokawa S; Kono M; Hashimoto D; Kamiya Y; Toyoshima M; Asada K; Morita M; Mikamo M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T Ther Adv Chronic Dis; 2022; 13():20406223221108395. PubMed ID: 35782342 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis. Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H Respir Med; 2019; 154():122-126. PubMed ID: 31238182 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113 [TBL] [Abstract][Full Text] [Related]
19. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072 [TBL] [Abstract][Full Text] [Related]
20. Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease. Suda T Clin Med Insights Circ Respir Pulm Med; 2015; 9(Suppl 1):155-62. PubMed ID: 27279757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]